title: [Efficacy of using VEGF165 gene in comprehensive treatment of patients with stage 2A-3 lower limb chronic ischaemia].
abstract: The authors share their experience in treating a total of 100 patients presenting with stage 2A-3 chronic lower limb ischaemia according to the classification of Pokrovsky-Fontain (the clinical group was composed of 75 patients and the control group comprised 25 subjects), in whom it was impossible to perform surgical revascularization. The clinical group patients received in addition to the conventional vascular therapy local intramuscular injections of Neovasculogen (plasmid genetic construction containing human gene VEGF165) at a course dose of 2.4 mg. The results were assessed after 1 year. It was shown that administration of this gene therapeutic agent is safe with no local or systemic allergic reactions and free form neoplastic processes. Efficacy of treatment was assessed by registering the pain-free walking distance (PFWD), transcutaneous oxygen tension (TCPO2), linear velocity of blood flow, ankle-brachial index (ABI), angiography, and by means of SF-36 questionnaire. It was determined that after 12 months the statistical significance of intergroup and intragroup differences was reached for PFWD (increment 167.2%), TCPO2 (increment 20.4%). The highest clinical response for the PFWD was registered in patients with stage 3 of the disease (547.5%), as well as in those with multi-storey vascular lesions (269.1%). The obtained findings make it possible to consider gene therapy with Neovasculogen as an efficient component of comprehensive treatment of this cohort of patients.
authors: R V
authors: RV
authors: Deev
authors: I Ia
authors: IIa
authors: Bozo
authors: N D
authors: ND
authors: Mzhavanadze
authors: E G
authors: EG
authors: Nersesian
authors: O V
authors: OV
authors: Chukhralia
authors: P G
authors: PG
authors: Shval'b
authors: Iu V
authors: IuV
authors: Cherviakov
authors: I N
authors: IN
authors: Staroverov
authors: R E
authors: RE
authors: Kalinin
authors: D A
authors: DA
authors: Voronov
authors: A V
authors: AV
authors: Gavrilenko
authors: A A
authors: AA
authors: Isaev
mesh_terms: D000328:Adult; D043925:Angiogenesis Inducing Agents / Q000008:administration & dosage; D000792:Angiography; D055109:Ankle Brachial Index; D001783:Blood Flow Velocity / Q000187:drug effects; D002908:Chronic Disease; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D007273:Injections, Intramuscular; D007511:Ischemia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D035002:Lower Extremity / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010101:Oxygen Consumption / Q000187:drug effects; D058729:Peripheral Arterial Disease / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D012039:Regional Blood Flow / Q000187:drug effects; D012720:Severity of Illness Index; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage*
chemical_list: D043925:Angiogenesis Inducing Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A